New osteoporosis drug shows promise in Head-to-Head trial
NCT ID NCT05345691
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 31 times
Summary
This study tested a new drug called Bmab 1000 against the approved drug Prolia in 479 postmenopausal women with osteoporosis. The goal was to see if Bmab 1000 works as well as Prolia at improving bone density and reducing bone breakdown. Participants received either Bmab 1000 or Prolia injections, and researchers measured changes in bone density and safety over a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
PPD Global Ltd, Granta Park, Great Abington,
Cambridge, UK, CB21 6GQ, United Kingdom
Conditions
Explore the condition pages connected to this study.